Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors

Neoplasma

Volumn 56, Issue 5, 2009, Pages 398-403

  Mego, M ^a,b   Rejlekova, K ^a,b   Reckova, M ^a   Sycova Mila, Z ^b   Obertova, J ^a,b   Rajec, J ^a,b   Mardiak, J ^a,b  

^a Faculty of Natural Sciences   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Germ cell cancer; Salvage chemotherapy; Serum tumor marker decline

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; ADOLESCENT; BLOOD; KINETICS; MIDDLE AGED; MORTALITY; NEOPLASM; PATHOLOGY; RETROSPECTIVE STUDY; TESTIS TUMOR;

ADOLESCENT; ADULT; ALPHA-FETOPROTEINS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; HUMANS; KINETICS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; RETROSPECTIVE STUDIES; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 69849110206     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_05_398     Document Type: Article

References (14)

1. EINHORN LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990; 8: 1777-1781. (Pubitemid 20382338)
2. MOTZER RJ, GELLER NL, TAN CC et al. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Ket tering Cancer Center experience (1979-1989). Cancer 1991; 67:1305-1310. doi:10.1002/1097-0142(19910301)67: 5〈1305::AID-CNCR2820670506>3.0.CO;2-J PMid:1703917
3. EINHORN LH. Clinical trials in testicular cancer. Cancer 1993; 71: 3182-3184. doi:10.1002/1097-0142(19930515)71:10〈3182::AID- CNCR2820711046〉3.0.CO;2-O PMid:8490849
4. MARDIAK J, SALEK T, SYCOVA-MILA Z et al. Paclitaxel, Bleomycin, Etoposide, and Cisplatin (T-BEP) as initial treatment in patients (pts) with poor-prognosis germ cell tumors (GCT): A phase II study. Neoplasma, 2007, 54: 240-245.
5. WILLIAMS SD, EINHORN LH, GRECO FA et al. VP-16-213 salvage therapy for refractory germinal neoplasm. Cancer 1980; 46: 2154-2158. doi:10.1002/1097- 0142(19801115)46:10〈2154::AID-CNCR2820461008〉3.0.CO;2-3 PMid:6159062
6. LOEHRER PJ, WILLIAMS SD, NICHOLS CR et al. Clinical trials with ifosfamide: The Indiana University experience. Semin Oncol 1992; 19: 35-39.
7. MARDIAK J, SALEK T, SYCOVA-MILA Z et al. Paclitaxel, ifosfamide, and cisplatin (TIP) salvage therapy for patients (pts) with relapsed testicular germ cell tumors (GCT). Neoplasma, 2005; 52: 497-501.
8. MARDIAK J, SALEK T, SYCOVÁ-MILA Z et al. Gemcitabine plus Cisplatine and Paclitaxel (GCP) in Second-line Treatment of Germ Cell Tumors (GCT): a phase II Study. Neoplasma, 2005; 52: 243-247. (Pubitemid 40776437)
9. REJLEKOVA K, MEGO M, SYCOVA-MILA Z et al. Prognostic factors in patients with relapsed or primary refractory germ cell tumors. Neoplasma. 2009; 56: 215-223.
10. FOSSA SD, OLIVER RT, STENNING SP et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer 1997; 33:1380-1387. doi:10.1016/S0959-8049(96)00425-X PMid:9337678 (Pubitemid 27404894)
11. FIZAZI K, CULINE S, KRAMAR A et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol. 2004; 22:3868-3876. doi:10.1200/JCO.2004.04.008 PMid:15302906
12. MASSARD C, KRAMAR A, PICO J et al. Does the kinetic of tumor marker decline predict outcome in patients with relapsed disseminated germ-cell tumors treated by high-dose or conventional chemotherapy? An analysis of the IT94 randomized trial. 2008 Genitourinary Cancers Symposium Proceedings. Abs. 288: 231.
13. MURPHY BA, MOTZER RJ, MAZUMDAR M et al. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 1994; 15: 2520-2526.
14. MOTZER RJ, NICHOLS CJ, MARGOLIN KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007; 25: 247-256. doi:10.1200/JCO.2005.05.4528 PMid:17235042